Thermo Fisher Scientific, Norway
Hany Meås, PhD
Staff Scientist
Topic: Novel Cell Isolation Platform with Active-Release Technology
2024 global R&D 100 Winner
This year, novel platform was recognized as one of TOP100 most innovative technologies in the global prestigious R&D 100 Awards. The R&D 100 Awards is the only science and technology awards competition that recognizes new products and technologies for their technological significance.
Cell therapy development and manufacture represents a transformative approach in modern medicine, offering potential cures for various conditions, including cancer and genetic disorders.
However, the generation of cell-based therapies deals with specific challenges, mainly, scalability, consistency, and regulatory compliance, which impact not only developers but patients as well. Addressing these pain points requires innovative solutions such as controllable cell activation process combined with automated and closed-system manufacturing, that are flexible and scalable.
Building upon our established Dynabeads™ and CaptureSelect™ technologies, the new Detachable Dynabeads feature an innovative active release mechanism.
The cell marker specific VHH ligands are conjugated to a low-affinity biotin derivative, allowing bead detachment from target cells via the competitive binding of biotin in the release buffer.
Optimized for the Gibco™ CTS™ DynaCellect™ Magnetic Separation System, this technology enables full automation and scalability in process development and clinical manufacturing.
-
-
R106
2024 global R&D 100 Winner: Novel Cell Isolation Platform with Active-Release Technology
Hany Meås (Thermo Fisher Scientific, Norway) & Lolita Zaliauskienė (Thermo Fisher Scientific, Lithuania)
-